[go: up one dir, main page]

MX2023000191A - Metodos de fabricacion y uso de inhibidores de pde9. - Google Patents

Metodos de fabricacion y uso de inhibidores de pde9.

Info

Publication number
MX2023000191A
MX2023000191A MX2023000191A MX2023000191A MX2023000191A MX 2023000191 A MX2023000191 A MX 2023000191A MX 2023000191 A MX2023000191 A MX 2023000191A MX 2023000191 A MX2023000191 A MX 2023000191A MX 2023000191 A MX2023000191 A MX 2023000191A
Authority
MX
Mexico
Prior art keywords
making
methods
pde9 inhibitors
pde9
inhibitors
Prior art date
Application number
MX2023000191A
Other languages
English (en)
Inventor
Jun Zhang
Liang Qin
Junhua Zhang
Niels Svenstrup
Jikui Sun
Yuyin Chen
Jianshe Kong
Rujian Ma
Huanming Xiao
Jinxu Sun
Xiao Meng
Fenglai Sun
Jingyang Zhu
Original Assignee
Imara Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Imara Inc filed Critical Imara Inc
Publication of MX2023000191A publication Critical patent/MX2023000191A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/485—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Dermatology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Inorganic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención se refiere a inhibidores de las PDE9, su síntesis y su uso, para el tratamiento de hiperplasia prostática benigna, beta talasemia y enfermedad de células falciformes.
MX2023000191A 2017-05-26 2019-11-22 Metodos de fabricacion y uso de inhibidores de pde9. MX2023000191A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201762511367P 2017-05-26 2017-05-26

Publications (1)

Publication Number Publication Date
MX2023000191A true MX2023000191A (es) 2023-02-09

Family

ID=64396048

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2019014049A MX2019014049A (es) 2017-05-26 2018-05-25 Metodos de fabricacion y uso de inhibidores de pde9.
MX2023000191A MX2023000191A (es) 2017-05-26 2019-11-22 Metodos de fabricacion y uso de inhibidores de pde9.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2019014049A MX2019014049A (es) 2017-05-26 2018-05-25 Metodos de fabricacion y uso de inhibidores de pde9.

Country Status (23)

Country Link
US (3) US11370795B2 (es)
EP (1) EP3630772B1 (es)
JP (1) JP7609518B2 (es)
KR (1) KR102627975B1 (es)
CN (2) CN115746003B (es)
BR (1) BR112019024877A2 (es)
CA (1) CA3064004A1 (es)
DK (1) DK3630772T3 (es)
EA (1) EA201992721A1 (es)
ES (1) ES2969895T3 (es)
FI (1) FI3630772T3 (es)
HR (1) HRP20240146T1 (es)
HU (1) HUE065158T2 (es)
IL (1) IL270792B2 (es)
LT (1) LT3630772T (es)
MA (1) MA48793A (es)
MX (2) MX2019014049A (es)
PL (1) PL3630772T3 (es)
PT (1) PT3630772T (es)
RS (1) RS65143B1 (es)
SI (1) SI3630772T1 (es)
TW (2) TWI843393B (es)
WO (1) WO2018218104A1 (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4335497A3 (en) 2015-07-07 2024-05-01 H. Lundbeck A/S Pde9 inhibitor with imidazo pyrazinone backbone for treatment of peripheral diseases
MX2019014049A (es) * 2017-05-26 2020-07-28 Imara Inc Metodos de fabricacion y uso de inhibidores de pde9.
MX2020012636A (es) 2018-05-25 2021-01-29 Imara Inc Formas de monohidrato y cristalinas de 6-[(3s,4s)-4-metil-1-(pirim idin-2- ilmetil)pirrolidin-3-il]-3-tetrahidropiran-4-il-7h-imidazo [1,5-a]pirazin-8- ona.
BR112021003686A2 (pt) 2018-08-31 2021-05-18 Imara Inc. inibidores de pde9 para tratar doença falciforme
CN109734653B (zh) * 2019-02-21 2020-07-14 北京悦康科创医药科技股份有限公司 一种阿加曲班起始原料异构体杂质的拆分方法
WO2020202183A1 (en) * 2019-03-29 2020-10-08 Mylan Laboratories Limited The process for the preparation of upadacitinib and its intermediates
JP2022527630A (ja) * 2019-04-05 2022-06-02 イマラ インク． 鎌状赤血球症を治療するためのｐｄｅ９阻害剤
WO2022036111A1 (en) * 2020-08-13 2022-02-17 Imara Inc. Methods and compositions for treating sickle cell disease

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5716988A (en) 1994-08-08 1998-02-10 Debiopharm S.A. Pharmaceutically stable preparation of oxaliplatinum
PT1368022E (pt) 2001-03-02 2007-10-01 Debiopharm Sa Utilização de um frasco em vidro que contém uma solução de oxaliplatina
PL370599A1 (en) * 2001-11-02 2005-05-30 Pfizer Products Inc. Treatment of insulin resistance syndrome and type 2 diabetes with pde9 inhibitors
AU2003284885A1 (en) 2002-10-21 2004-05-13 Kensey Nash Corporation Device and methods for sequential, regional delivery of multiple cytotoxic agents
GB0522569D0 (en) 2005-11-04 2005-12-14 Univ Bath Biocompatible drug delivery device
GEP20125405B (en) * 2007-05-11 2012-02-27 Pfizer Amino-heterocyclic compounds
TWI404721B (zh) 2009-01-26 2013-08-11 Pfizer 胺基－雜環化合物
WO2012040230A1 (en) 2010-09-20 2012-03-29 Envivo Pharmaceuticals, Inc. Imidazotriazinone compounds
IN2015DN02829A (es) * 2011-10-10 2015-09-11 Lundbeck & Co As H
CN107082783B (zh) 2012-01-26 2019-03-22 H.隆德贝克有限公司 具有咪唑并三嗪酮骨架的pde9抑制剂
US10058688B2 (en) 2012-05-09 2018-08-28 Massachusetts Institute Of Technology Medicament, method, and drug delivery device for treatment of ovarian cancer
ES2902833T3 (es) 2012-08-31 2022-03-30 Taris Biomedical Llc Sistemas y métodos de administración de fármacos para el tratamiento de cáncer de vejiga que comprenden oxaliplatino
EP2983730B1 (en) 2013-04-10 2019-10-16 Massachusetts Institute of Technology Local drug delivery devices and methods for treating cancer
WO2015023557A1 (en) 2013-08-12 2015-02-19 Nanomedical Systems, Inc. Device and method for sustained release of low water solubility therapeutic agent in solubilizer
EP4335497A3 (en) * 2015-07-07 2024-05-01 H. Lundbeck A/S Pde9 inhibitor with imidazo pyrazinone backbone for treatment of peripheral diseases
MX2019014049A (es) 2017-05-26 2020-07-28 Imara Inc Metodos de fabricacion y uso de inhibidores de pde9.

Also Published As

Publication number Publication date
CN111183140A (zh) 2020-05-19
TWI791021B (zh) 2023-02-01
JP7609518B2 (ja) 2025-01-07
PT3630772T (pt) 2024-02-05
EA201992721A1 (ru) 2020-09-10
CN111183140B (zh) 2022-12-02
FI3630772T3 (fi) 2024-01-31
BR112019024877A2 (pt) 2020-06-09
JP2020527535A (ja) 2020-09-10
IL270792A (en) 2020-01-30
CN115746003A (zh) 2023-03-07
ES2969895T3 (es) 2024-05-23
EP3630772A4 (en) 2021-01-13
MA48793A (fr) 2020-04-08
TW202334156A (zh) 2023-09-01
IL270792B2 (en) 2024-01-01
CN115746003B (zh) 2024-08-09
KR102627975B1 (ko) 2024-01-19
US20250019381A1 (en) 2025-01-16
EP3630772A1 (en) 2020-04-08
HRP20240146T1 (hr) 2024-04-12
US11999741B2 (en) 2024-06-04
SI3630772T1 (sl) 2024-05-31
EP3630772B1 (en) 2023-11-01
TW201908319A (zh) 2019-03-01
RS65143B1 (sr) 2024-02-29
DK3630772T3 (da) 2024-02-05
US11370795B2 (en) 2022-06-28
PL3630772T3 (pl) 2024-08-05
US20200157108A1 (en) 2020-05-21
LT3630772T (lt) 2024-02-26
WO2018218104A1 (en) 2018-11-29
KR20200016891A (ko) 2020-02-17
CA3064004A1 (en) 2018-11-29
IL270792B1 (en) 2023-09-01
MX2019014049A (es) 2020-07-28
TWI843393B (zh) 2024-05-21
HUE065158T2 (hu) 2024-05-28
US20230183244A1 (en) 2023-06-15

Similar Documents

Publication Publication Date Title
MX2022010638A (es) Inhibidores de pde9 para el tratamiento de enfermedades perifericas.
MX2023000191A (es) Metodos de fabricacion y uso de inhibidores de pde9.
MX2020012797A (es) Anticuerpos biespecificos anti-pvrig/anti-tigit y métodos de uso.
MX2017009571A (es) Inhibidores heterociclicos de itk para el tratamiento de la inflamacion y cancer.
MX2020010496A (es) Inhibidores de desmetilasa-1 especifica de lisina.
MD20150085A2 (ro) Inhibitori ai histon-demetilazelor
EP4335497A3 (en) Pde9 inhibitor with imidazo pyrazinone backbone for treatment of peripheral diseases
PH12015500963A1 (en) Tricyclic fused thiophene derivatives as jak inhibitors
EA201270100A1 (ru) Пиримидиноны в качестве ингибиторов pi3k
NZ720478A (en) Autotaxin inhibitor compounds
TW201613919A (en) Inhibitors of Bruton's tyrosine kinase
MX2022008523A (es) Compuestos que interactuan con glicanos y metodos de uso.
EA201790085A1 (ru) Ингибиторы лизин-специфической деметилазы-1
MX2016017407A (es) Inhibidores de histona demetilasa.
SA519410320B1 (ar) مركبات فينيل -2-هيدروكسي-أسيتيل أمينو -2-ميثيل-فينيل
MX2020006365A (es) Quinazolinonas como inhibidores de poli(adenosin difosfato-ribosa)polimerasa 14 (parp14).
TW201625535A (en) Inhibitors of histone demethylases
MX2016014436A (es) Derivados de heterociclil-butanamida.
CL2017000659A1 (es) Inhibidores de histona desmetilasa
MX382092B (es) Compuestos heterocíclicos para el tratamiento de enfermedades.
MX2020005342A (es) Compuestos de pirazolopiridinona.
MX2020005344A (es) Compuestos de pirazolopiridinona.
MX2016008042A (es) Derivados de imidazopirazinona.
EA201790604A1 (ru) Ингибиторы гистондеметилазы
MX2018005515A (es) Derivados de 1,4-dicarbonil-piperidilo.